Founded in 1995 by three people diagnosed with Alpha-1 Antitrypsin (AAT) Deficiency, a genetic condition that may result in serious lung disease in adults and/or liver disease at any age, the Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of those affected worldwide.
To advance this mission, the foundation is inviting LOIs for its research grants program. Through the program, grants of up to $100,000 a year for up to two years will be awarded in support of research that contributes to the understanding of the basic biology of AAT expression and the pathogenesis/management of AAT Deficiency. Consideration also will be given to those projects that provide insight into the development of information that may contribute to new therapies for AAT Deficiency.
Letters of Intent are due November 13. Upon review, selected applicants will be invited to submit a full application by January 15, 2021.
See the Alpha-1 Foundation for complete program guidelines and application instructions.